middle.news
Invex Therapeutics Expands Alzheimer’s Research with New GLP-1 Combinations
6:14pm on Thursday 23rd of July, 2026 AEST
•
Healthcare
Read Story
Invex Therapeutics Expands Alzheimer’s Research with New GLP-1 Combinations
6:14pm on Thursday 23rd of July, 2026 AEST
Key Points
Expanded preclinical program targets Alzheimer's with Exenatide combinations
Focus on neuroprotection and ferroptosis mechanisms in AD model
Cash reserves declined to $4.02 million from $4.52 million
Operating cash outflows rose to $501,000, driven by R&D and admin costs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invex Therapeutics (ASX:IXC)
OPEN ARTICLE